Oct 2, 2023 Press Releases
PDF Version AT-01 is a first-in-class pan-amyloid imaging agent capable of detecting diverse types of systemic amyloidosis in multiple organs. AT-01 demonstrated to be highly accurate, with 100% sensitivity for detection of cardiac amyloid, across three independent...
Apr 3, 2023 Press Releases
PDF Version AT-04 demonstrated sub nanomolar binding to Aβ, tau and α-synuclein fibrils AT-04 demonstrated in vivo target engagement and binding to Aβ plaques in the brain AT-07 (AT-04 + Brain Shuttle) demonstrated a 10-fold increase in brain penetration versus AT-04...
Dec 19, 2022 Press Releases
PDF Version SAN FRANCISCO – December 19, 2022 – Attralus, Inc., a clinical stage biopharmaceutical company developing transformative medicines to improve the lives of patients with systemic amyloidosis, announced today that the European Commission (EC) and European...
Oct 17, 2022 Press Releases
PDF Version SAN FRANCISCO, Calif. – October 17, 2022 – Attralus, Inc., a clinical stage biopharmaceutical company developing transformative medicines to improve the lives of patients with systemic amyloidosis, today announced that the first subject has been dosed in...
Sep 8, 2022 Press Releases
PDF Version AT-01 is a first-in-class pan-amyloid imaging agent capable of detecting diverse types of systemic amyloidosis in multiple organs Sensitivity in those with previously diagnosed cardiac disease was 100% in ATTR and 93% in AL Organ-specific changes in...
